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Abstract 
RON is a tyrosine kinase receptor activated by the MSP ligand that is overexpressed 
in human breast cancer. In humans, RON protein can be present in different 
isoforms, and the most studied isoform is represented by the short form of RON (sf-
RON), which is generated by an alternative promoter located in intron 10 of the RON 
cDNA. It plays an important role in breast cancer progression. Considering the many 
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similarities between feline mammary tumors and human breast cancer, the aim of 
this study was to investigate the expression of both RON and MSP in feline 
mammary carcinomas (FMCs) and to identify the presence of the sf-RON transcript. 
Tissue samples of spontaneous mammary tumors were collected from 60 queens (10 
benign lesions and 50 carcinomas). All of the samples were tested for RON and MSP 
expression by immunohistochemistry; moreover, RNA was extracted from paraffin-
embedded tissue samples, and the cDNA was tested by RT-PCR to identify the 
presence of sf-RON. IHC detected the expression of RON and MSP in 34/50 (68%) 
and 29/50 (58%) of FMCs, respectively. RT-PCR revealed the presence of the short-
form in 18/47 (38.3%) of FMCs. This form originates, as in humans, from an 
alternative promoter (P2) and it codes for the proper feline short form (sf-RON). sf-
RON expression was statistically associated with poorly differentiated tumors and 
with a shorter disease-free (DFI) period and a shorter survival (OS). These results 
support FMC as a suitable model in comparative oncology and identify sf-RON 
expression as a potential predictor of outcomes for this disease.  
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Introduction 
Since 1980, feline mammary carcinoma (FMC) has been recognized as a suitable 
animal model for studying human breast cancer since it shares histological, 
molecular and clinical features with human breast carcinoma.5,12,14,33 
3 
 
RON/stk proto-oncogene, a member of the MET family, is a tyrosine kinase receptor 
that is abnormally overexpressed in a variety of human cancers including breast 
cancer. 20,30 The mouse homologue of human RON receptor, called stk, was 
identified in 1995,15 while the feline homologue of the corresponding gene and 
protein, feline stk/RON, was first characterized in 2002.11 Macrophage stimulating 
protein (MSP) is RON’s specific ligand and it is present both in tissue and in 
circulating blood. Downstream signaling targets of RON activity include PI3K, Src, 
FAK, AKT and MAPK, which can lead to proliferation, cell survival, cell motility, cell 
shape changes and invasion in cancer.9,10 
Following alternative splicing, both the human RON and the homologous mouse stk 
genes can generate different isoforms of the receptor lacking the extracellular 
domain of the receptors but conserving its catalytic activity. 28,13 The two major 
transcripts are the full-length transcript that encodes the full-size RON receptor and 
the short form of RON (sf-RON), also called the truncated form. In humans, the full 
length of RON consists of 20 exons encoding a 180 kDa protein with 1400 amino 
acids while the sf-RON is generated by an alternative promoter (5’UTR) located 
within intron 10 of the mRNA, regulating the transcription of sf-RON from the 
transcription initiation nucleotide represented by guanine2519.2 The presence of intron 
10 in the RON transcript suggests the presence of sf-RON in tissues and cell lines,3 
and furthermore, the expression of both of the transcripts has been demonstrated to 
be associated with different methylation sites within RON promoters.2 Figure 1 shows 
a schematic of the RON gene structure and transcriptional regulation of the full length 
and short form.  
In humans, sf-RON was detected, at very low levels, in colon, skin and lung tissue 
but not in bone marrow, bone marrow-derived cells, human muscle or brain.13,28 
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However, some reports in human medicine have demonstrated the presence of sf-
RON in cells derived from breast cancer, lung cancer, pancreatic cancer and 
leukemia. It has also been correlated with invasive capability in vitro,3,4 and 
alternatively spliced RON transcripts have been reported in other types of cancers.17-
19 In addition, it has been reported that sf-RON proteins are constitutively active since 
they are able to confer growth advantages to cells and have been involved in the 
epithelial-mesenchymal transition (EMT).8 
In breast cancer, the presence of sf-RON is correlated with a poor prognosis and 
tumor recurrence.18 Moreover, the recent development of specific RON inhibitors in 
combination with PI3K inhibitors with demonstrated antitumor activity suggest an 
important role of sf-RON in terms of targeted therapies. 7,32  
In consideration of the significant homologies between feline and human mammary 
tumors, the aim of this research was to investigate the expression of both isoforms of 
RON receptor and its ligand MSP in a large cohort of FMC tissues and cell lines and 
to identify the presence of the sf-RON transcript in FMC in relation to 
clinicopathologic findings.  
 
Materials and methods 
Cell lines  
Six primary cell lines derived from FMC (FYCp, FKNp, FNNm, FMCp, FMCm and 
P248) and spontaneously immortalized were tested in the in vitro 
experiments21,24,25,29. FYCp, FKNp, FNNm, FMCp, and FMCm were maintained in 
RPMI medium supplemented with 10% fetal bovine serum (FBS), 5000 IU/mL 
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penicillin, 5 mg/mL streptomycin, and 2 mM L-glutamine; the P248 cell line was 
maintained in DMEM under the same conditions but with the addition of 10 mg/ml 
insulin to the medium.22 The human GTL-16 gastric carcinoma cell line was used as 
a positive control in western blot analysis and grown in DMEM as previously 
described.31  
 
Tissue samples and histological examination 
Tissue samples from spontaneous cases of feline mammary tumors and normal 
mammary tissues were collected from the 2009–2013 archives of the Diagnostic 
Laboratories of the Department of Veterinary Sciences of the University of Turin 
(Italy) and from the Department of Animal Pathology, University of Córdoba (Spain). 
Details of age, breed, ovariectomy status and tumor size data were retrieved from the 
hospital database. Each animal was surgically treated with mastectomy (partial or 
total) and free surgical margins were histologically confirmed; this retrospective study 
has been approved by the ethical committee of the Department of Veterinary Science 
according to institutional guidelines.  
Postoperative clinical, radiological and echographic examinations at 6, 12, 18 and 24 
months after surgery were performed to detect the presence of distant organ 
metastases or local relapse. Animals that died due to mammary carcinoma were 
submitted for post-mortem examination to confirm the pathological diagnosis; 
subjects that died of nontumor-related causes (confirmed by necropsy) during the 
follow-up period were excluded from the study. The disease-free interval (DFI) was 
considered as the number of days between surgery and tumor recurrence and/or 
evidence of metastatic disease, while overall survival (OS) was considered as the 
period between surgery and death. Normal mammary tissues used as a control were 
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collected from necropsy (after the owners’ consent). Samples were fixed in 4% 
neutral buffered formalin, paraffin embedded, sectioned at 4 µm and stained with 
hematoxylin and eosin (H&E). Samples were histologically examined and classified 
according to the World Health Organization (WHO) classification for tumors of 
domestic animals,26 and surgical margins were evaluated to confirm that all tumor 
masses were completely surgically ablated. Carcinomas were graded according to 
Mills and colleagues (2014).23 
 
Immunohistochemistry  
Immunohistochemical (IHC) analysis was performed on 4 µm paraffin sections from 
all collected samples; immunocytochemistry was performed on all cultured cell 
pellets that were similarly fixed, embedded, and sectioned. After endogenous 
peroxidase activity blockade with 3% hydrogen peroxide for 20 min at room 
temperature, sections were subjected to high-temperature antigen retrieval by 
incubation with 98°C citric acid buffer (pH 6.0). Primary antihuman antibodies were 
used against RON β diluted 1:150, overnight incubation (C-20 rabbit polyclonal 
antibody; catalogue number sc-322, Santa Cruz Biotechnology, Dallas, Texas, USA) 
and against MSP diluted 1:50, overnight incubation (rabbit monoclonal antibody; 
catalogue number EPR6207, Abcam, Cambridge, UK). Antibodies were detected 
with avidin-biotin-peroxidase complexes using the Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, USA). Positive controls for RON and MSP were 
represented by lung and lymph node tissues, respectively. For the negative controls, 
positive control tissues were incubated with normal rabbit and mouse IgG (Santa 
Cruz Biotechnology, Dallas, Texas, USA). Immunostaining evaluation was performed 
independently by two observers (LM and SI); when there was disagreement, a 
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consensus was obtained using a multi-head microscope. Samples were scored 
semiquantitatively according to the intensity of membranous and/or cytoplasmic 
staining for both RON and MSP according to Ren and colleagues (2012) (0 = no 
staining, 1+ = weak staining, 2+ = moderate staining, 3+ = strong staining). Samples 
with absent or weak immunostaining (score 0 and 1+) were defined as negative, and 
those with moderate to strong immunostaining (score 2+ and 3+) as positive.27 In the 
supplemental Figures S1–S8 examples of each score are shown.   
 
Protein extraction and western blot analysis 
Total proteins were extracted from 3 cases of feline mammary carcinomas (FMC1, 
FMC2 and FMC3) collected at the Veterinary Hospital of the Department of 
Veterinary Science of Turin and from the FYC cell line; normal feline spleen tissue 
from necroscopy was used as a negative control while protein lysate from GTL16 
was used as a human positive control. Total proteins were extracted with fresh RIPA 
buffer solution (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) containing a 
protease inhibitor cocktail (Sigma-Aldrich, Saint Louis Missouri, USA). Two hundred 
micrograms of total protein from each sample were separated on 9% SDS-
polyacrylamide (PAGE) gels, transferred onto Hybond-C Extra membranes 
(Amersham Biosciences, Bath, UK) and incubated overnight at 4°C with a primary 
antibody against RON. After washing three times in PBS-Tween for 15 min and 
incubating with a horseradish peroxidase (HRP)-linked secondary antibody diluted 
1:2000 in PBS-Tween 0.01%, the membranes were washed in PBS-Tween for 30 
min and then incubated with an enhanced chemiluminescence reagent (Super Signal 
West Pico Rabbit IgG Detection Kit, Thermo Scientific, Waltham, USA).  
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DNA extraction and sequencing of genomic feline RON exon 10–exon 14 
Genomic DNA was extracted from normal feline lymphoid tissue (spleen) using a 
QIAamp DNA mini kit (Qiagen, Hilden, Germany). PCR was performed on 100 ng of 
total genomic DNA using HotStart AmpliTAQ (Qiagen, Hilden, Germany), and 
amplification of the genomic region of the feline RON corresponding to exon 8 to 
exon 14 was performed. Sequences of exonic primers P1 and P2 are shown in 
Supplemental Table S1 and were designed on the basis of the sequence of feline 
RON cDNA present in the gene bank (XP_003982293). The PCR protocol for all 
primers was as follows: 1 cycle at 95°C for 5 min, 30 cycles (95°C 1 min, 60°C 1 min, 
72°C 1 min), and 1 cycle at 72°C for 7 min. After purification of specific amplified 
bands from agarose by the QIAquick gel extraction kit (Qiagen, Hilden, Germany), 
direct sequencing of PCR products was performed using the BigDye Terminator V 
3.1 Sequencing Kit and ABIPRISM 310 Genetic Analyzer (Applied Biosystem, Foster 
City California, USA).  
  
c-DNA preparation, PCR and sequencing of sf-RON 
Total RNA was extracted from paraffin-embedded tissues of FMCs, benign lesions 
and normal mammary glands using an RNA FFPE extraction kit (Qiagen, Hilden, 
Germany) and from six FMC cell lines (FYCp, P248m, FKNp, FNNm, FMCp, and 
FMCm) using the TRIzol method (Sigma-Aldrich, Saint Louis Missouri, USA). The 
quality of the RNA was evaluated using the Experion Automated Electrophoresis 
System (BioRad, Hercules, California, USA), and samples with degraded RNA were 
excluded. cDNA was synthesized from 1 μg of total RNA using the QuantiTect 
Reverse Transcription kit (Qiagen, Hilden, Germany) including genomic DNA 
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removal as described in the procedures of the kit. To examine the RON transcript, 
endpoint RT-PCR was performed with primer P3 sense and P4 antisense 
(Supplemental Table S1) in a final volume of 20 µl using HotStart TAQ (Qiagen, 
Hilden, Germany). The PCR conditions were as follows: 1 cycle at 95°C for 5 min, 30 
cycles (95°C 1 min, 60°C 1 min, 72°C 1 min) and 1 cycle at 72°C for 7 min. 
Moreover, to exclude genomic DNA contamination, PCR of intronic sequences 
corresponding to intron 12 and 13 of the feline RON gene was performed on cDNA 
(data not shown).  
Amplification products obtained from RT-PCR were extracted from the agarose by a 
QIAquick gel extraction kit (Qiagen, Hilden, Germany) and directly sequenced using 
a BigDye Terminator V 3.1 Sequencing Kit and an ABI PRISM 310 Genetic Analyzer 
(Applied Biosystem, Foster City California, USA). Amplification of feline GAPDH was 
used as the housekeeping gene. The presence of CpG islands was assessed and we 
submitted the sequence to the online software available at 
http://dbcat.cgm.ntu.edu.tw/. 
 
Statistical analysis 
IHC results, molecular data and clinicopathologic findings were grouped into 
contingency tables and analyzed using Fisher's exact test or Chi2 test. Survival 
curves were computed using the Kaplan–Meier method and tests for differences in 
survival, considering all known prognostic factors for FMC, were performed using the 
log-rank test. OS was defined as the number of days between surgery and death, 
while the DFI was defined as the number of days between surgery and tumor 
recurrence and/or evidence of metastasis. Censored data were considered as those 
cases that were still alive or that did not present with tumor recurrence or metastasis 
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at the end of the monitoring period. Data were analyzed with MedCalc Statistical 
Software v.13.3 (MedCalc Software bvba, Ostend, Belgium); P < 0.05 was 
considered statistically significant. 
  
RESULTS 
 
Epidemiologic and clinical data  
Sixty queens with mammary lesions were enrolled in this study. Their mean age was 
11.3 years (range: 8–17 years) and their epidemiologic and clinical data are 
summarized in Table 1. Histological examination resulted in 50 FMC and 10 benign 
lesions. Four normal mammary tissues (from archives) were also evaluated as 
controls.  
Regarding queens with a diagnosis of FMC, at the time of diagnosis, histologically 
confirmed lymph node metastases were present in 2/50 (4%) cases and no clinically 
or radiographically observable distant organ metastases were present; 10/50 (20%) 
queens did not present with tumor recurrence while 40/50 (80%) relapsed between 2 
and 23 months after surgery. The median OS recorded was 180 days (range 45–730 
days). Forty out of 50 cases developed pulmonary metastases during the follow-up 
period and died of cancer-related causes as confirmed at postmortem examination. 
Ten censored cases were included in this study. 
Histopathology 
The histopathological examination resulted in 10 benign mammary lesions and 50 
carcinomas. The histopathological results are summarized in Table 2.  
Immunohistochemistry 
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Immunoreactivity to MSP (Figure 2 and 4) and RON (Figure 3 and 5) proteins, if 
present, were observed in the cytoplasm of FMC cell lines and carcinomas. IgG 
control staining is shown in Supplemental Figure S9. Immunoreactive products were 
not observed in normal mammary glands (Supplemental Figure S10). Regarding the 
expression of RON and MSP in benign lesions, 3/10 (two adenomas and one 
fibroadenoma) were positive for RON, while 2/10 (one adenoma and one 
fibroadenoma) were positive for MSP. In FMCs, RON was positive in 34/50 (68%) of 
cases and MSP was positive in 29/50 (58%) of cases. A total of 52% of FMCs 
expressed both RON and MSP, and a statistically significant association was found 
between the expression of these two antibodies (P <0.05). 
No statistical correlation was found between the immunohistochemical results for 
RON and MSP in relation to the clinicopathologic findings in the 50 FMC cases 
(Table 3). 
Genomic Sequence of Feline RON 
Sequences of DNA coding for feline RON from exon 10 to exon 14 were obtained 
from normal spleen and the sequences of the gene, mRNA and CDS (coding 
sequence) with exon-intron junctions were submitted to GenBank with the accession 
number KT248534.  
Identification of feline sf-RON 
As previously described and to examine the presence of sf-RON in our samples, RT-
PCR was performed with P1 and P2 primers designed to amplify exon 10 or exon 11 
of the feline cDNA. PCR products obtained from the amplification showed two bands, 
the larger containing intron 10 in the cDNA sequence and co-migrating with normal 
feline DNA, and a lower band, containing the full-length feline RON but not containing 
intron 10. Both of the bands obtained were automatically sequenced and this 
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revealed that the highest band corresponded to sf-RON. sf-RON was detected in 
18/47 (38.3%) of FMCs (3/50 cases were excluded from analysis because the RNA 
was degraded) and in 4/6 cell lines; benign tumors and normal mammary gland 
tissue did not express feline sf-RON. Figure 6 shows the rationale used to amplify sf-
RON. In Supplemental Figure S11, RT-PCR products obtained from cDNA templates 
from the cell lines are shown. 
Statistical analysis revealed that queens that were FMC positive for the sf-RON had 
both a shorter DFI (median 180 days vs. 635 days; HR 2.2, 95% CI, 1.04–4.6) and a 
shorter OS (median 365 days vs. 755 days; HR 2.2, 95% CI, 1.03–4.7) compared 
with queens with tumors negative for sf-RON (Figure 7 and Figure 8). Moreover, 
FMC positivity for sf-RON was statistically associated with poorly differentiated 
histological grade (Table 4).  
To demonstrate if intron 10 in felines also contained typical CpG island regions acting 
as alternative promoter regions, the entire sequence was submitted to the software 
available at http://dbcat.cgm.ntu.edu.tw/. From this analysis, we found that the region 
corresponding to intron 10 contained more than 66% of the CpG islands 
(Supplemental Figure S12).  
Protein Analysis  
Feline mammary carcinoma samples (FMC1, FMC2, and FMC3) corresponding to 
poorly differentiated (FMC1 and FMC2) and moderately differentiated mammary 
carcinomas (FMC3) were collected. Protein analysis revealed that all FMCs 
examined and the FYC cell line expressed the precursor of RON at different levels 
resulting in a protein of 180 kDa co-migrating with the human control represented by 
the GTL16 cell line (Figure 9). As shown, the beta chain isoform in humans 
corresponds to 150 kDa while in feline samples it corresponds to 135 kDa, as 
13 
 
previously demonstrated by the same authors,11 and it was present in all analyzed 
FMCs at different levels. 
Conversely, in all samples, a specific band corresponding to 55 kDa was detected, 
confirming the presence of the short form in feline samples and in the FYC cell line 
that expresses sf-RON, as also shown in RT PCR (see Supplemental Figure S11); 
feline spleen resulted in negative findings for both isoforms (Figure 9). The presence 
of additional protein bands migrating at 72–90 kDa should be referred to as HMW-
sfRON (high molecular weight–sfRON) as already demonstrated in human breast 
cancer,18,19 which is recognized by the same antibody. 
 
DISCUSSION 
In this article, we provide evidence that the truncated form of RON kinase is 
expressed in feline mammary tumors and that its expression represents a prognostic 
factor in this type of tumor. The presence of the RON transcript in feline mammary 
tumors was first demonstrated in 2002 when the authors partially identified the gene 
coding for full-length RON protein.11 In humans and mice, the gene coding for sf-
RON is regulated by an internal promoter (P2) located in intron 101 as shown in 
Figure 1. To demonstrate if this isoform was also present in felines, the authors first 
determined the genomic sequence of feline RON from exon 8 to exon 14 and its 
intron/exon junctions; these data showed a high homology with human, canine and 
murine sequences and were submitted to the GenBank database. On the basis of the 
feline intron 10 sequence and adopting the molecular approach published by 
Bardella and colleagues (2004),3 the authors evaluated the presence of both sf-RON 
by endpoint RT-PCR in cDNA from FMC cell lines and the RON protein from tissue 
samples from feline mammary tumors. The results obtained from RT-PCR on tissues 
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demonstrated the presence of sf-RON in 38.3% of feline mammary carcinomas and 
in 4/6 of feline mammary cell line transcripts. In all of the samples, the sequence of 
amplicons revealed the insertion of intron 10 (P2). Moreover, in benign lesions and 
normal mammary glands, sf-RON was not detected. These results were confirmed by 
western blot analysis of FMCs samples and the FYC cell line. In Figure 9, all 
samples, at different levels, showed the mature form of the feline RON migrating at 
135 kDa, as previously demonstrated by the same authors,11 while sf-RON is 
detectable at 55 kDa in feline FMCs, FYC cell lines and human controls represented 
by GTL16; feline spleen was negative for both isoforms. In this experiment, the 
authors also detected also protein products migrating at 72–95 kDa. These proteins, 
as demonstrated in human breast cancer18, can be referred to other isoforms called 
sf-RON-HMW (short form high molecular weight) derived from further different 
splicing of the human RON gene to be able to generate protein products of 
approximately 72–95 kDa.19 The identification of sf-RON-HMW isoforms was also 
performed in human breast cancer tissues using the same antibody by Liu et al,18 
and this suggests that the presence of these isoforms should be investigated in the 
feline. 
Overall, these data suggest that in feline species sf-RON originates, as in humans, 
from the alternative promoter (P2) located in intron 10. In particular, analyzing the 
nucleotide sequence “corresponding” to intron 10, we found a high percentage of 
possible CpG islands with a GC content of 66%, suggesting, as in humans, that RON 
gene transcription may be regulated by a promoter in the CpG islands region. 
Moreover, the presence of sf-RON was significantly associated with a poorly 
differentiated histological grade, with a shorter disease-free (DFI) period and a 
shorter survival (OS). Regarding this aspect, there is no data available as to the 
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prognostic value of sf-RON in breast cancer patients. Otherwise, our results 
according to the human literature suggest that the presence of sf-RON confers 
aggressiveness of breast cancer in in vitro and in vivo conditions and it is able to 
convert slow-growing and nonmetastatic tumors into rapidly growing tumors and 
promotes epithelial–mesenchymal transitions via PI3K pathways18, confirming the 
importance of this protein in breast cancer progression, as already demonstrated in 
feline mammary carcinomas.21,22 
Immunohistochemical expression of the RON receptor and its specific ligand MSP 
were observed in 68% and 58% of FMCs, respectively, while 52% of cases 
coexpressed both proteins. However, no correlation was observed between 
immunohistochemical expression of the RON receptor or its ligand MSP with 
clinicopathologic and survival data. The antibody used in this study for the detection 
of RON protein (C-20) recognizes the COOH terminus of the protein (intracellular 
portion), which is present in both isoforms (full and short). Thus, IHC data could not 
differentiate between the two isoforms in tissues. These considerations could explain 
the lack of correlation between IHC expression of RON/MSP and the clinical 
outcomes compared with expression of sf RON assessed by RT-PCR. 
Our IHC data confirm our previous results in feline mammary tumors 11 and are 
similar to the human literature where RON is expressed in 50% of primary breast 
carcinomas but does not represent a prognostic factor.20  
No data are available in human breast cancer regarding the association between the 
presence of sf-RON and the clinical findings, although it is known that this isoform, 
through its interaction with PI3K, is able to promote metastasis.18  
The relevance of sf-RON in human cancer is an emerging and interesting topic due 
to the development of specific molecules able to inhibit RON receptor activity34 and 
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recently the potential use of molecules able to inhibit RON have been studied in 
cancers of the pancreas, lung, colon and breast. 6,16,17,35 As previously discussed, 
FMC highly resembles human breast cancer, sharing histopathological, clinical and 
molecular features 12,14,33. In this study, we demonstrated that in vitro and in vivo 
feline mammary tumors present with the truncated form of RON and its presence is 
significantly associated with high grade of tumor and a worse prognosis.  
As shown in Figure 7 and Figure 8, after 100 days there is no apparent effect of sf-
RON on the DFI and OS, but its role seems to appear in a later phase. This tendency 
suggests that in the early stages of tumor progression sf-RON is not involved, but in 
the later stages, further additional pathways participate in tumor progression. 
These results support FMC as a suitable model in comparative oncology and identify 
sf-RON expression as having potential in predicting the outcomes of this disease.  
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Figure legends 
Figure 1: RON/stk gene structure and transcriptional regulation of the full length and 
short form, respectively. 
Figure 2: cell line from metastasis of mammary carcinoma, cat, case FNNm.  
Immunocytochemistry for MSP. Moderate positivity (score 2+) in all neoplastic cells   
Figure 3: cell line from metastasis of mammary carcinoma, cat, case FNNm. 
Immunocytochemistry for RON. Moderate positivity (score 2+) in all neoplastic cells  
Figure 4: Adenocarcinoma, mammary gland, cat. Immunohistochemistry for MSP. 
Moderate membrane stain for MSP (score 2+) in neoplastic cells. . 
Figure 5: Adenocarcinoma, mammary gland, cat. Immunohistochemistry for RON. 
Moderate membrane stain for RON (score 2+) in neoplastic cells. 
Figure 6: Regulation of full length and short forms of feline RON gene receptor and 
RT-PCR products obtained from FMCs (feline mammary carcinomas). The higher 
and lower bands correspond respectively to short and full-length forms of RON. K1-
K7 corresponds to feline mammary carcinomas while NTC is the non-template 
control. GAPDH was used as the housekeeping gene control.  
Figure 7: Kaplan–Meier survival curve of disease-free intervals (DFI) in FMCs (feline 
mammary carcinomas): total mean DFI: 407 days; mean sf/RON positive samples 
326 days; mean sf/RON negative samples 510 days (log-rank test: P < 0.05). The 
expression of sf RON has been determined by RT-PCR. 
Figure 8: Kaplan–Meier survival curve of overall survival (OS) in FMCs (feline 
mammary carcinomas): total mean OS: 466 days; mean sf/RON positive samples 
387 days; mean sf/RON negative samples 568 days (log-rank test: P < 0.05). The 
expression of sf RON has been determined by RT-PCR. 
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Figure 9: Western blot against RON of protein lysates from three feline mammary 
carcinomas (FMC1, FMC2 and FMC3), FYC cell line, feline spleen and the human 
GTL16 cell line. fl-RON and sf-RON are present in all FMCs samples at different 
levels. Feline spleen showing non-specifc bands and GTL16 represent, respectively, 
negative and human positive controls.  
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Table 1 Relation between Clinico-pathologic features and Immunohistochemical results 
  
Clinicopathologic 
characteristics 
RON+ 
n (%) 
RON- 
n (%) P 
MSP+ 
n (%) 
MSP - 
n (%) 
P 
 
  
** 
   
MSP+ 26 (52%) 3 (6%) < 0.001 
   
MSP-  8 (16%) 13 (26%) 
    
Total 34 16 
    
 
      
>1 cm 
 24 
(48%) 
 14(28%) >0.05 21 (42%) 17 (34%) >0.05 
≤1 cm 10 (20%) 2 (4%) 
 
8 (16%) 4 (8%) 
 
Total 34 16 
 
29 21 
 
 
      
Grade I 8 (16%) 1 (2%) >0.05 4 (8%) 5 (10%) >0.05 
Grade II 11 (22%) 8 (16%) 
 
10 (20%) 9 (18%) 
 
Grade III 15 (30%) 7 (14%) 
 
15(30%) 7 (14%) 
 
Total 34 16 
 
29 21 
 
 
      
Vascular invasion 8 (16%) 5 (10%) >0.05 9 (18%) 4 (8%) >0.05 
No vascular invasion 26 (52%) 11 (22%) 
 
20 (40%) 17 (34%) 
 
Total 34 16 
 
29 21 
 
 
      
Relapsed 0-6 months 13(26%) 11 (22%) >0.05 14 (28%) 10 (20%) >0.05 
Relapsed 6-12 months 7 (14%) 3 (6%) 
 
7 (14%) 3 (6%) 
 
Relapsed >12 months 5 (10%) 1 (2%) 
 
2 (4%) 4 (8%) 
 
Not relapsed 9 (18%) 1 (2%) 
 
6 (12%) 4 (8%) 
 
Total 34 16 
 
29 21 
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